95 related articles for article (PubMed ID: 23746837)
1. Fixing a hole where the Ras gets in.
Iwig JS; Kuriyan J
Cell; 2013 Jun; 153(6):1191-3. PubMed ID: 23746837
[TBL] [Abstract][Full Text] [Related]
2. Anticancer drugs: A new approach for blocking KRAS.
Tse MT
Nat Rev Drug Discov; 2013 Jul; 12(7):506. PubMed ID: 23787956
[No Abstract] [Full Text] [Related]
3. Cancer: Drug for an 'undruggable' protein.
Baker NM; Der CJ
Nature; 2013 May; 497(7451):577-8. PubMed ID: 23698372
[No Abstract] [Full Text] [Related]
4. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling.
Zimmermann G; Papke B; Ismail S; Vartak N; Chandra A; Hoffmann M; Hahn SA; Triola G; Wittinghofer A; Bastiaens PI; Waldmann H
Nature; 2013 May; 497(7451):638-42. PubMed ID: 23698361
[TBL] [Abstract][Full Text] [Related]
5. Structure guided design and kinetic analysis of highly potent benzimidazole inhibitors targeting the PDEδ prenyl binding site.
Zimmermann G; Schultz-Fademrecht C; Küchler P; Murarka S; Ismail S; Triola G; Nussbaumer P; Wittinghofer A; Waldmann H
J Med Chem; 2014 Jun; 57(12):5435-48. PubMed ID: 24884780
[TBL] [Abstract][Full Text] [Related]
6. Structure-based development of PDEδ inhibitors.
Martín-Gago P; Fansa EK; Wittinghofer A; Waldmann H
Biol Chem; 2017 May; 398(5-6):535-545. PubMed ID: 27935847
[TBL] [Abstract][Full Text] [Related]
7. Identification of pyrazolopyridazinones as PDEδ inhibitors.
Papke B; Murarka S; Vogel HA; Martín-Gago P; Kovacevic M; Truxius DC; Fansa EK; Ismail S; Zimmermann G; Heinelt K; Schultz-Fademrecht C; Al Saabi A; Baumann M; Nussbaumer P; Wittinghofer A; Waldmann H; Bastiaens PI
Nat Commun; 2016 Apr; 7():11360. PubMed ID: 27094677
[TBL] [Abstract][Full Text] [Related]
8. Targeting the K-Ras/PDEδ protein-protein interaction: the solution for Ras-driven cancers or just another therapeutic mirage?
Frett B; Wang Y; Li HY
ChemMedChem; 2013 Oct; 8(10):1620-2. PubMed ID: 23939923
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanism of the association and dissociation of Deltarasin from the heterodimeric KRas4B-PDEδ complex.
Bello M; Correa-Basurto J; Vargas-Mejía MÁ
Biopolymers; 2019 Nov; 110(11):e23333. PubMed ID: 31568570
[TBL] [Abstract][Full Text] [Related]
10. The KRAS-PDEδ interaction is a therapeutic target.
Cancer Discov; 2013 Jul; 3(7):OF20. PubMed ID: 23847364
[TBL] [Abstract][Full Text] [Related]
11. Targeting RAS: The Elusive Prize.
Bates SE
Clin Cancer Res; 2015 Apr; 21(8):1796. PubMed ID: 25878359
[No Abstract] [Full Text] [Related]
12. Inhibition of ras oncogene: a novel approach to antineoplastic therapy.
Scharovsky OG; Rozados VR; Gervasoni SI; Matar P
J Biomed Sci; 2000; 7(4):292-8. PubMed ID: 10895051
[TBL] [Abstract][Full Text] [Related]
13. Stabilization of the RAS:PDE6D Complex Is a Novel Strategy to Inhibit RAS Signaling.
Yelland T; Garcia E; Parry C; Kowalczyk D; Wojnowska M; Gohlke A; Zalar M; Cameron K; Goodwin G; Yu Q; Zhu PC; ElMaghloob Y; Pugliese A; Archibald L; Jamieson A; Chen YX; McArthur D; Bower J; Ismail S
J Med Chem; 2022 Feb; 65(3):1898-1914. PubMed ID: 35104933
[TBL] [Abstract][Full Text] [Related]
14. Novel Ras pathway inhibitor induces apoptosis and growth inhibition of K-ras-mutated cancer cells in vitro and in vivo.
Jasinski P; Zwolak P; Terai K; Dudek AZ
Transl Res; 2008 Nov; 152(5):203-12. PubMed ID: 19010291
[TBL] [Abstract][Full Text] [Related]
15. Specificity of inhibition of ras-p21 signal transduction by peptides from GTPase activating protein (GAP) and the son-of sevenless (SOS) ras-specific guanine nucleotide exchange protein.
Chie L; Chung D; Pincus MR
Protein J; 2005 May; 24(4):253-8. PubMed ID: 16283548
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Ras for cancer treatment: the search continues.
Baines AT; Xu D; Der CJ
Future Med Chem; 2011 Oct; 3(14):1787-808. PubMed ID: 22004085
[TBL] [Abstract][Full Text] [Related]
17. Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways.
Janda E; Lehmann K; Killisch I; Jechlinger M; Herzig M; Downward J; Beug H; Grünert S
J Cell Biol; 2002 Jan; 156(2):299-313. PubMed ID: 11790801
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Novel KRAS-PDEδ Inhibitors by Fragment-Based Drug Design.
Chen L; Zhuang C; Lu J; Jiang Y; Sheng C
J Med Chem; 2018 Mar; 61(6):2604-2610. PubMed ID: 29510040
[TBL] [Abstract][Full Text] [Related]
19. Direct Attack on RAS: Intramolecular Communication and Mutation-Specific Effects.
Marcus K; Mattos C
Clin Cancer Res; 2015 Apr; 21(8):1810-8. PubMed ID: 25878362
[TBL] [Abstract][Full Text] [Related]
20. H-Ras is a negative regulator of alpha3beta1 integrin expression in ECV304 endothelial cells.
Shin EY; Lee JY; Park MK; Jeong GB; Kim EG; Kim SY
Biochem Biophys Res Commun; 1999 Apr; 257(1):95-9. PubMed ID: 10092516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
